Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Subscribe To Our Newsletter & Stay Updated